RxDoctor Payments Data

Charlton Strange, MD

Critical Care Medicine · Charleston, SCNPI 1427155217

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $131,483 of the $204,587 with a category attached, or 64.3%. 18 manufacturers reported payments, led by CSL Behring at 29.4% of the total. Among critical care medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$204,587in general payments, 2019–2025

Across 196 payments — averaging $1043.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$60K
  • AstraZeneca$44K
  • GSK$27K
  • Sanofi$19K
  • F. Hoffmann-la Roche AG$17K
  • Takeda Pharmaceuticals U.S.A., Inc.$11K
  • plus $27K from 12 others
$1,160,077in research payments, 2019–2025

Across 308 payments — averaging $3766.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$413K
  • Grifols Therapeutics LLC$279K
  • Vertex$192K
  • Shire North American Group Inc$111K
  • Biomarin Pharmaceutical Inc.$94K
  • Grifols Biologicals LLC$60K
  • plus $12K from 2 others

What the payments were for

  • Consulting fees$131,48364%
  • Speaking & faculty fees$30,04415%
  • Travel & lodging$37,85819%
  • Food & beverage$5,1303%
  • Education$720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$204,587 in reported general payments places this provider in the 95th percentile of 93 critical care medicine providers in South Carolina.

See all critical care medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$36,852
Medicare patients
153
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZemairaAlpha-1-Proteinase Inhibitor37$456,423
Aralast NpAlpha-1-Proteinase Inhibitor17$340,333
Prolastin CAlpha-1-Proteinase Inhibitor21$192,864
Ambrisentan11$52,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$26,236
Spiriva RespimatTiotropium Bromide21$19,089
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$11,152
Spiriva HandihalerTiotropium Bromide15$8,431
Combivent RespimatIpratropium/Albuterol Sulfate14$7,931
Breo ElliptaFluticasone/Vilanterol14$6,204
SymbicortBudesonide/Formoterol Fumarate13$4,922
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,598
Albuterol Sulfate HfaAlbuterol Sulfate26$1,231
Prednisone51$327
Azithromycin12$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringZemaira$60,154$456,42337 claims
Grifols USA, LLCProlastin C$6,827$192,86421 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$141$38,17251 claims
GSKTrelegy Ellipta, Breo Ellipta$26,617$32,44136 claims
AstraZenecaSymbicort$43,667$4,92213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 critical care medicine providers in South Carolina.

Other critical care medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →